LAB

MKT CAP:$354M

Standard BioTools Inc.

Market Cap

$354M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Healthcare·Medical - Devices·🇺🇸·NASDAQ

Stock Price

$0.89-$0.38 (-29.61%)

Apr 23, 2026

Company Details

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Mi...

CEO

Michael Egholm

IPO Date

Feb 10, 2011

Website

www.standardbio.com

Key Metrics TTM

Revenue

$85M

-46.6% YoY

Net Income

-$75M

EPS (Diluted)

-$0.20

Free Cash Flow

-$83M

Revenue / Share

$0.22

Gross Margin

49.9%

Operating Margin

-109.3%

Net Margin

-87.8%

FCF Margin

-96.9%

P/S

4.2x

P/E

—

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Mar 16, 2026

$85M-51.1%EPS -$0.20

Q4 2025

Mar 16, 2026

$3M-93.1%EPS $0.05

Q3 2025

Nov 4, 2025

$20M-56.5%EPS -$0.09

Q2 2025

Aug 15, 2025

$22M-3.2%EPS -$0.09

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$27M	$12M	-$28M
Q2 22	$19M	$4M	-$39M
Q3 22	$26M	$9M	-$29M
Q4 22	$27M	$11M	-$21M
Q1 23	$25M	$12M	-$17M
Q2 23	$28M	$14M	-$17M
Q3 23	$25M	$11M	-$21M
Q4 23	$28M	$13M	-$21M
Q1 24	$46M	$24M	-$60M
Q2 24	$22M	$10M	-$30M
Q3 24	$45M	$23M	-$32M
Q4 24	$47M	$22M	-$33M
Q1 25	$41M	$20M	-$33M
Q2 25	$22M	$11M	-$26M
Q3 25	$20M	$9M	-$23M
Q4 25	$3M	$3M	-$11M

Valuation

Quarter	P/S	P/E
Q1 22	2.2x	—
Q2 22	1.2x	—
Q3 22	0.8x	—
Q4 22	1.3x	—
Q1 23	1.5x	—
Q2 23	1.5x	—
Q3 23	2.1x	—
Q4 23	5.9x	—
Q1 24	7.9x	—
Q2 24	5.3x	—
Q3 24	5.1x	—
Q4 24	4.1x	—
Q1 25	2.5x	—
Q2 25	2.9x	—
Q3 25	3.7x	—
Q4 25	5.7x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$16M	-$16M
Q2 22	-$30M	-$31M
Q3 22	-$25M	-$26M
Q4 22	-$19M	-$20M
Q1 23	-$8M	-$9M
Q2 23	-$9M	-$10M
Q3 23	-$11M	-$12M
Q4 23	-$14M	-$14M
Q1 24	-$62M	-$63M
Q2 24	-$39M	-$41M
Q3 24	-$28M	-$30M
Q4 24	-$14M	-$17M
Q1 25	-$30M	-$35M
Q2 25	-$21M	-$23M
Q3 25	-$22M	-$23M
Q4 25	-$1M	-$2M

Capital Expenditures

Quarter	CapEx
Q1 22	$868.0K
Q2 22	$938.0K
Q3 22	$1M
Q4 22	$755.0K
Q1 23	$1M
Q2 23	$838.0K
Q3 23	$905.0K
Q4 23	$78.0K
Q1 24	$781.0K
Q2 24	$2M
Q3 24	$2M
Q4 24	$3M
Q1 25	$5M
Q2 25	$2M
Q3 25	$886.0K
Q4 25	$476.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-19.2%	+3.6%
Q2 22	-39.5%	+18.8%
Q3 22	-10.0%	+13.6%
Q4 22	-29.4%	-2.8%
Q1 23	-5.2%	-22.8%
Q2 23	+47.3%	-21.3%
Q3 23	-1.1%	-14.9%
Q4 23	+4.3%	+3.0%
Q1 24	+81.3%	+153.5%
Q2 24	-18.7%	+16.9%
Q3 24	+77.3%	+64.8%
Q4 24	+65.7%	+60.4%
Q1 25	-10.4%	-30.2%
Q2 25	-3.2%	-10.0%
Q3 25	-56.5%	-43.9%
Q4 25	-93.1%	-81.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$4M	15.3%
Q2 22	$5M	24.8%
Q3 22	$4M	17.5%
Q4 22	$2M	6.2%
Q1 23	$3M	12.5%
Q2 23	$3M	11.3%
Q3 23	$3M	13.3%
Q4 23	$3M	12.3%
Q1 24	$4M	7.8%
Q2 24	$7M	29.9%
Q3 24	$6M	13.2%
Q4 24	$7M	16.0%
Q1 25	$9M	22.1%
Q2 25	$5M	24.7%
Q3 25	$8M	38.5%
Q4 25	$6M	178.2%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 22	$9M	$31M
Q2 22	$13M	$30M
Q3 22	$8M	$26M
Q4 22	$8M	$24M
Q1 23	$6M	$21M
Q2 23	$6M	$23M
Q3 23	$6M	$22M
Q4 23	$7M	$21M
Q1 24	$16M	$47M
Q2 24	$7M	$25M
Q3 24	$13M	$34M
Q4 24	$14M	$38M
Q1 25	$11M	$39M
Q2 25	$6M	$28M
Q3 25	$6M	$27M
Q4 25	$8M	$25M

Revenue Segments

Quarter	Product	Service
Q3 22	$19M	$6M

Revenue by Geography

Quarter	Americas	Asia Pacific	Emea
Q1 22	$13M	$5M	$9M
Q2 22	$9M	$4M	$6M
Q3 22	$11M	$6M	$8M
Q4 22	$11M	$6M	$11M
Q1 23	$12M	$6M	$8M
Q2 23	$10M	$6M	$11M
Q3 23	$11M	$6M	$8M
Q4 23	$13M	$6M	$9M
Q1 24	$25M	$8M	$13M
Q3 24	$24M	$5M	$16M
Q1 25	$19M	$9M	$13M
Q2 25	$9M	$4M	$9M
Q3 25	$8M	$4M	$7M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$30M	$0	$30M
Q2 22	$74M	$137M	$211M
Q3 22	$60M	$125M	$185M
Q4 22	$81M	$84M	$166M
Q1 23	$114M	$41M	$155M
Q2 23	$142M	$0	$142M
Q3 23	$80M	$49M	$129M
Q4 23	$52M	$63M	$115M
Q1 24	$287M	$175M	$462M
Q2 24	$270M	$125M	$395M
Q3 24	$211M	$156M	$366M
Q4 24	$167M	$126M	$293M
Q1 25	$151M	$107M	$258M
Q2 25	$159M	$78M	$237M
Q3 25	$129M	$65M	$195M
Q4 25	$118M	$69M	$188M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	77M	+0.5%	+3.1%
Q2 22	78M	+1.0%	+3.1%
Q3 22	79M	+1.4%	+3.4%
Q4 22	79M	+0.7%	+3.6%
Q1 23	79M	-0.4%	+2.7%
Q2 23	79M	-0.5%	+1.1%
Q3 23	79M	+0.6%	+0.3%
Q4 23	80M	+0.7%	+0.4%
Q1 24	294M	+268.9%	+271.9%
Q2 24	372M	+26.6%	+373.3%
Q3 24	372M	-0.2%	+369.4%
Q4 24	375M	+0.8%	+369.8%
Q1 25	378M	+1.0%	+28.6%
Q2 25	380M	+0.6%	+2.2%
Q3 25	383M	+0.6%	+3.0%
Q4 25	385M	+0.6%	+2.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$43.1K	615
Q2 22	$30.5K	615
Q3 22	$41.7K	615
Q4 22	$51.7K	523
Q1 23	$48.0K	523
Q2 23	$52.9K	523
Q3 23	$48.5K	523
Q4 23	$30.4K	928
Q1 24	$49.1K	928
Q2 24	$24.2K	928
Q3 24	$48.5K	928
Q4 24	$57.1K	818
Q1 25	$49.9K	818
Q2 25	$26.6K	818
Q3 25	$23.9K	818
Q4 25	$8.3K	389

Revenue / Employee